Медицинская литература. Новинки

 

 

 

 

 

 

Диагностическая визуализация при олигометастатической болезни. Общие вопросы (краткий обзор литературы)

Вы можете загрузить полный текст статьи в формате pdf

Введение. Визуализация олигометастатической болезни является сложной диагностической задачей, поскольку требуется определение точной локо-регионарной стадии онкологического заболевания и оценки состояния всего тела пациента в плане возможного выявления полиметастатического состояния в виде обнаружения диссеминированных метастазов. Учитывая данное обстоятельство, довольно часто требуется сочетание методов визуализации. Цель исследования: проанализировать возможности современных методов диагностической визуализации при олигометастической болезни и определить дальнейшие направления их развития.Заключение. Диагностическая визуализация крайне важна при реализации стандартных методов современного противоопухолевого лечения (оценка ответа на проведенное специальное лечение солидных опухолей с помощью компьютерной томографии, магнитно-резонансной томографии и сцинтиграфии костей), а также расширенных методов визуализации (функциональных, метаболических и радионуклидное таргетирование) для выявления и динамического наблюдения за пациентами с олигометастатической болезнью.

Ключевые слова:
олигометастическая болезнь, диагностическая визуализация, будущие направления развития, oligometastatic disease, diagnostic imaging, future directions of development

Литература:
1.Паньшин Г.А. Роль дистанционной стереотаксической абляционной радиотерапии тела при олигометастатической болезни (общие вопросы). Вопросы онкологии. 2023; 69 (4): 599–604. https://doi.org/10.37469/0507-3758-2023-69-4-599-604
2.Джабаров Ф.Р., Альникин А.Б., Толмачев В.Г. Олигометастатический рак предстательной железы: диагностика и предварительные результаты лучевого лечения. Вестник урологии. 2020; 8 (2): 55–66. https://doi.org/10.21886/2308-6424-2020-8-2-55-66
3.Salama J.K., Hasselle M.D., Chmura S.J. et al. Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer. 2012; 118: 2962–2970. https://doi.org/10.1002/cncr.26611
4.Rini B.I., Dorff T.B., Elson P. et al. Active surveillance in metastatic renalcell carcinoma: A prospective, phase 2 trial. Lancet Oncol. 2016; 17: 1317–1324. https://doi.org/10.1016/S1470-2045(16)30196-6
5.Hellman S., Weichselbaum R.R. Oligometastases. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1995; 13: 8–10. https://doi.org/10.1200/JCO.1995.13.1.8
6.De Ruysscher D., Wanders R., van Baardwijk A. et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J. Thorac. Oncol. 2012; 7 (10): 1547–1555. https://doi.org/10.1097/JTO.0b013e318262caf6
7.Andrews D.W., Scott C.B., Sperduto P.W. et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004; 363 (9422): 1665–1672. https://doi.org/10.1016/S0140-6736(04)16250-8
8.Guckenberger M., Lievens Y., Bouma A.B. et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21 (1): e18–e28. https://doi.org/10.1016/S1470-2045(19)30718-1
9.Алексеев Б.Я., Нюшко К.М., Крашенинников А.А., Сафронова Е.Ю., Сергиенко С.А., Калпинский А.С., Воробьев Н.В., Каприн А.Д. Методы диагностики и лечения олигометастазов у больных раком предстательной железы с прогрессированием заболевания после проведенного радикального лечения. Онкоурология. 2016; 12 (2): 64–73. https://doi.org/10.17650/1726-9776-2016-12-2-64-73
10.Гомболевский В.А., Харламов К.А., Масри А.Г., Ким С.Ю., Морозов С.П. Общие рекомендации по описанию первичных и повторных КТ, МРТ, рентгенологических исследований / Cерия “Лучшие практики лучевой и инструментальной диагностики”. Вып. 2. М., 2017. 20 с.
11.deSouza N.M., Liu Y., Chiti A. et al. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur. J. Cancer. 2018; 91: 153–163. https://doi.org/10.1016/j.ejca.2017.12.012
12.Ruf J., Schiefer J., Furth C. et al. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: Spotlight on the CT phases of a triple-phase protocol. J. Nucl. Med. 2011; 52: 697–704. https://doi.org/10.2967/jnumed.110.083741
13.Park H.J., Kim H.J., Kim K.W. et al: Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT. Eur. Radiol. 2020; 30: 4772–4782. https://doi.org/10.1007/s00330-020-06867-w
14.Howe J.R., Cardona K., Fraker D.L. et al. The surgical management of small bowel neuroendocrine tumors: Consensus guidelines of the North American neuroendocrine tumor society. Pancreas. 2017; 46: 715–731. https://doi.org/10.1097/MPA.0000000000000846
15.Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract. Res. Clin. Gastroenterol. 2012; 26: 803–818. https://doi.org/10.1016/j.bpg.2012.12.004
16.Raptopoulos V.D., Blake S.P., Weisinger K. Multiphase contrastenhanced helical CT of liver metastases from renal cell carcinoma. Eur. Radiol. 2001; 11: 2504–2509. https://doi.org/10.1007/s003300100853
17.O'Sullivan G.J., Carty F.L., Cronin C.G. Imaging of bone metastasis: An update. Wld J. Radiol. 2015; 7: 202–211. https://doi.org/10.4329/wjr.v7.i8.202
18.Talbot J.N., Paycha F., Balogova S. Diagnosis of bone metastasis: Recent comparative studies of imaging modalities. Q. J. Nucl. Med. Mol. Imaging. 2011; 55: 374–410. PMID: 21738113
19.Yang H.-L., Liu T., Wang X.-M. Diagnosis of bone metastases: A metaanalysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur. Radiol. 2011; 21: 2604–2617. https://doi.org/10.1007/s00330-011-2221-4
20.O'Sullivan G.J., Carty F.L., Cronin C.G. Imaging of bone metastasis: An update. Wld J. Radiol. 2015; 7 (8): 202–211. https://doi.org/10.4329/wjr.v7.i8.202
21.Liu B., Gao S., Li S. A Comprehensive Comparison of CT, MRI, Positron Emission Tomography or Positron Emission Tomography/CT, and Diffusion Weighted Imaging-MRI for Detecting the Lymph Nodes Metastases in Patients with Cervical Cancer: A Meta-Analysis Based on 67 Studies. Gynecol. Obstet. Invest. 2017; 82 (3): 209–222. https://doi.org/10.1159/000456006
22.Ramalho J., Semelka R.C., Ramalho M. Gadolinium-based contrast agent accumulation and toxicity: An update. Am. J. Neuroradiol. 2016; 37: 1192–1198. https://doi.org/10.3174/ajnr.A4615
23.McDonald R.J., Levine D., Weinreb J. et al. Gadolinium retention: A research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. Radiology. 2018; 289: 517–534.
24.Padhani A.R., Liu G., Koh D.M. et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: Consensus and recommendations. Neoplasia. 2009; 11: 102–125. https://doi.org/10.1593/neo.81328
25.Tsao J. Ultrafast imaging: principles, pitfalls, solutions, and applications. J. Magn. Reson. Imaging. 2010; 32: 252–266. https://doi.org/10.1002/jmri.22239
26.Expert Panel on Radiation Oncology-Brain Metastases / Lo S.S., Gore E.M., Bradley J.D., Buatti J.M. et al. ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases. J. Palliat. Med. 2014; 17 (8): 880–886. https://doi.org/10.1089/jpm.2014.9417
27.Morrow M., Waters J., Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet. 2011; 378 (9805): 1804–1811. https://doi.org/10.1016/S0140-6736(11)61350-0
28.Zwittag P., Asel C., Gabriel M. et al. MRI and PET/CT in the assessment of lymph node metastases in head and neck cancer. Sci. Rep. 2023; 13 (1): 19347. https://doi.org/10.1038/s41598-023-46845-y
29.Mizukami Y., Ueda S., Mizumoto A. et al. Diffusion-weighted magnetic resonance imaging for detection of colorectal cancer lymph node metastases. Wld J. Surg. 2011; 35: 895–899. https://doi.org/10.1007/s00268-011-0986-x
30.Chong A., Hwang I., Ha J.M. et al. Application of bone scans for prostate cancer staging: Which guideline shows better result? Can. Urol. Assoc. J. 2014; 8 (7–8): E515–519. https://doi.org/10.5489/cuaj.2054
31.Van den Wyngaert T., Strobel K., Kampen W.U. et al. Practical recommendations of EANM for bone scintigraphy. Euro. J. Nucl. Honey. Mol. Visualization. 2016; 43: 1723–1738. https://doi.org/10.1007/s00259-016-3415-4
32.Izmailov T., Ryzhkin S., Borshchev G., Boichuk S. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials. Cancers. 2023, 15 (21), 5234. https://doi.org/10.3390/cancers15215234
33.Cook G.J.R., Goh V. Molecular Imaging of Bone Metastases and Their Response to Therapy. J. Nucl. Med. 2020; 61 (6): 799–806. https://doi.org/10.2967/jnumed.119.234260
34.Hicks R.J., Roselt P.J., Kallur K.G. et al. FAPI PET/CT: will it end the hegemony of (18)F-FDG in oncology? J. Nucl. Honey. 2021; 62: 296–302. https://doi.org/10.2967/jnumed.120.256271
35.Kahle J., Ceci F., Eiber M. et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-center, single-arm comparative imaging study. Lancet Oncol. 2019; 20: 1286–1294. https://doi.org/10.1016/S1470-2045(19)30415-2
36.McConathy J. 18F-Fluciclovine (FACBC) and Its Potential Use for Breast Cancer Imaging. J. Nucl. Med. 2016; 57 (9): 1329–1330. https://doi.org/10.2967/jnumed.116.175489
37.Durante S., Dunet V., Gorostidi F. et al. Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study. EJNMMI Res. 2020; 10 (1): 47. https://doi.org/10.1186/s13550-020-00638-w.
38.Farwell M.D., Gamache R.F., Babazada H. et al. PET imaging targeting CD8 tumor-infiltrating T cells in patients with cancer: a first-in-human phase I study of (89)Zr-Df-IAB22M2C, a radiolabeled anti-CD8 mini-antibody. J. Nucl. Med. 2022; 63 (5) 720–726. https://doi.org/10.2967/jnumed.121.262485
39.Fernandez M, Javaid F, Chudasama V. Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem. Sci. 2017; 9 (4): 790–810. https://doi.org/10.1039/c7sc04004k
40.Boss S.D., Ametami S.M. Development of folate receptor-targeted PET radiopharmaceuticals for tumor imaging – from bench to bedside. Cancer. 2020; 12 (6): 1508. https://doi.org/10.3390/cancers12061508
41.Gnessin S., Muller J., Burger I.A. et al. Radiation dosimetry of (18)F-AzaFol: first use of a PET tracer of the folic acid receptor in humans. EJNMMI Res. 2020; 10 (1): 32. https://doi.org/10.1186/s13550-020-00624-2
42.Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68 (6): 394–424. https://doi.org/10.3322/caac.21492. Erratum in: CA Cancer J. Clin. 2020; 70 (4): 313. https://doi.org/10.3322/caac.21492
43.Viale P.H. The American Cancer Society's Facts & Figures: 2020 Edition. J. Advanced Pract. Oncol. 2020; 11 (2): 135–136. https://doi.org/10.6004/jadpro.2020.11.2.1

Diagnostic imaging for oligo metastatic disease. General questions (a brief review of the literature)

Brief Summary. Visualization of oligometastatic disease (OMD) is a complex diagnostic task, since it requires determining the exact loco-regional stage of cancer and assessing the condition of the patient's entire body in terms of possible detection of polymetastatic condition in the form of detection of disseminated metastases. Given this circumstance, quite often a combination of visualization methods is required.Purpose of the study: to analyze the possibilities of modern diagnostic imaging methods for oligo metastatic disease and determine the further directions of their development.Conclusion. Diagnostic imaging is extremely important in the implementation of standard methods of modern antitumor treatment (assessment of the response to special treatment of solid tumors using computed tomography, magnetic resonance imaging and bone scintigraphy), as well as advanced imaging methods (functional, metabolic and radionuclide targeting) to identify and dynamically monitor patients with oligometastatic disease.

Keywords:
олигометастическая болезнь, диагностическая визуализация, будущие направления развития, oligometastatic disease, diagnostic imaging, future directions of development